To test whether MLL1 gene expression can be used as a biomarker to detect the incidence of MLL1‐rearrangement in solid tumors, we compared the expression of MLL1 gene in leukemia patients that harbor MLL1‐fusion with the expression in those who do not harbor this fusion (Fig. 2D). This evidence concerns the gene KMT2A and leukemia.